Biomarin Technologies B.V.
Records under this name other than the patents Biomarin Technologies B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.
Back to Biomarin Technologies B.V.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,890,379 | Treatment of Genetic Disorders Associated with DNA Repeat Instability Formerly held In force · High confidence | In force | High confidence | |
| US 10,689,646 | Treatment Of Genetic Disorders Associated With DNA Repeat Instability Formerly held In force · High confidence | In force | High confidence | |
| US 11,274,299 | Methods and means for treating DNA repeat instability associated genetic disorders Formerly held In force · High confidence | In force | High confidence | |
| US 9,499,818 | Methods and Means for Efficient Skipping of at Least One of the Exons 51-53, 55, 57 and 59 of the Human Duchenne Muscular Dystrophy Gene Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,876,114 | Methods and Means for Efficient Skipping of at Least One of the Following Exons of the Human Duchenne Muscular Dystrophy Gene: 43, 46, 50-53 Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,139,828 | Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,745,576 | RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders Formerly held In force · High confidence | In force | High confidence | |
| US 11,459,358 | Substances for Targeting Various Selected Organs or Tissues Lapsed on the fee record Ended Oct 4, 2026 · High confidence | Lapsed on the fee record | Ended Oct 4, 2026 | High confidence |
| US 8,268,962 | Molecules for targeting compounds to various selected organs or tissues Lapsed on the fee record Ended Sep 18, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 18, 2024 | From the USPTO record |
| US 8,802,645 | Molecule for Treating an Inflammatory Disorder Lapsed on the fee record Ended Aug 12, 2022 · High confidence | Lapsed on the fee record | Ended Aug 12, 2022 | High confidence |